

Clinical trial results:

A Randomised three-arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in metastatic Uveal Melanoma Summary

Results information	
Trial information	
Trial identification	
Additional study identifiers	
Sponsors	
Paediatric regulatory details	

Results analysis stage	
General information about the tri	ial
	
Population of trial subjects	
Subjects enrolled per country	
Subjects onvelled now are arranged	
Subjects enrolled per age group	

 <u> </u>

Subject disposition Recruitment **Pre-assignment** Period 1 Arms Arm title **Arm title**

Arm title	

Number of subjects in period 1		



Reporting groups Reporting group values

Baseline characteristics

	ı	
	<u> </u>	
Subject analysis sets		
Reporting group values		

I	I	

End points				
End points reporting groups	ı			
	'			
Primary: Progression Free Survi	val			
Filliary: Progression Free Survi	vai			
	_	Γ	Γ	
End point values				
Statistical analyses Statistical analysis title				
	1			

Secondary: Time To Treatment Failure End point values
End point values


Statistical analyses
Statistical analysis title


	•		
	I		
Secondary: Overall Survival			
	l		
	 		
End point values			
End point values			
Statistical analyses			
	1		
Statistical analysis title			
	!		


Secondary: Response Rate			
	î	-	
End point values			
Statistical analyses			
Statistical analysis title			
	1		
	<u> </u>		


Adverse events information Dictionary used Reporting groups Serious adverse events

Adverse events











Non-serious adverse events		

Non-serious adverse events		





More information

Substantial protocol amendments (globally)

Date	Amendment